LR Health & Beauty's 10.398% Bond Fuels 2024 Growth Surge

• LR Health & Beauty SE reported a sales increase to EUR 289.2 million in 2024, a 4.6% rise from the previous year.
• The company's EBITDA for 2024 was EUR 27.3 million, impacted by one-off extraordinary effects, with a normalized EBITDA of EUR 32.6 million.
• A realignment of the career plan significantly boosted new sales careers and contributed to the sales increase.
• The successful launch of the LR Aloe Via Magic Power Duo skincare range and other products contributed to a positive business outlook for 2025.
• LR Health & Beauty SE forecasts a significant increase in EBITDA for 2025, with stable to moderate sales growth expected.
• The company focuses on expanding its product portfolio and digital offerings, aiming for sustained profitable growth in the health and beauty sectors.

The price of LR Health & Beauty Unternehmensanleihe 10,398 % bis 03/28 at the time of the news was 95,63EUR and did not change compared to the previous day.

LR Health & Beauty Unternehmensanleihe 10,398 % bis 03/28

0,00 %

-1,57 %

-1,44 %

-1,57 %

+0,37 %

-1,09 %

ISIN:NO0013149658WKN:A3513A

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• Max